Alan Tan

We can all agree ertifitinib is pretty rough, and it's not a very popular choice for our patients unless they actually have this mutation and they have nothing else clinical trial-wise.

But as you mentioned, the Forager trial, this is a Loxolili trial, really good data on the safety and efficacy, even post-ertifitinib so far, right?

Yeah.

What do you guys think about moving this into the front line with EV Pembroke?

Like, is this then a cruel?

They're doing a worldwide study called Forager 2.

And I think as an academic oncologist, I would enroll patients in this study.

Why?

Because I know that these are the ones that are going to be refractory to chemo and to EV Pembroke, right?

I have too many examples where these patients are refractory.

So I'd rather...

get them on a well-tolerated FGFR inhibitor in that triplet setting.

But I think many people and many of our colleagues in community colleges are like, why do we need to do better than EV-Pembroke?

EV-Pembroke is so good, right?

It's true, but there is a subset that is really tough.

Yeah, really exciting times, guys.

Thanks so much for the discussion tonight.

Let's close up here.

What are you guys excited about?

What do you guys want to happen next in bladder urethelial cancer?